Published in N Engl J Med on October 17, 1968
Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J Clin Invest (1995) 2.27
The Role of PPARα Activation in Liver and Muscle. PPAR Res (2010) 1.07
Modulation of the gating of CIC-1 by S-(-) 2-(4-chlorophenoxy) propionic acid. Br J Pharmacol (1999) 1.00
Ten years clinical experience with partial ileal bypass in management of the hyperlipidemias. Ann Surg (1974) 0.98
Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. Br Med J (1971) 0.94
Paradoxical effects of clofibrate on liver and muscle metabolism in rats. Induction of myotonia and alteration of fatty acid and glucose oxidation. J Clin Invest (1979) 0.93
Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle. Am J Pathol (2010) 0.93
Hypothyroidism masquerading as polymyositis. Postgrad Med J (1982) 0.92
Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report. Acta Neuropathol (1985) 0.88
Clofibrate, serum enzymes, and muscle pain. Br Med J (1970) 0.86
Effects of clofibric acid on the activity and activity state of the hepatic branched-chain 2-oxo acid dehydrogenase complex. Biochem J (1992) 0.83
Branched chain amino acid oxidation in cultured rat skeletal muscle cells. Selective inhibition by clofibric acid. J Clin Invest (1980) 0.80
Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation. J Inherit Metab Dis (2007) 0.79
The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia. Br J Clin Pharmacol (1984) 0.78
Bezafibrate induced rhabdomyolysis. Ann Rheum Dis (1992) 0.75
Classification of lipoproteins and lipoprotein disorders. J Clin Pathol Suppl (Assoc Clin Pathol) (1973) 0.75
Therapy of lipid disorders. J Clin Pathol Suppl (Assoc Clin Pathol) (1973) 0.75
Aspects of mixed connective tissue disease: a review. J R Soc Med (1992) 0.75
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta (1972) 9.02
Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med (1967) 6.51
Chaperonin-mediated protein folding at the surface of groEL through a 'molten globule'-like intermediate. Nature (1991) 6.20
DnaK, DnaJ and GrpE form a cellular chaperone machinery capable of repairing heat-induced protein damage. EMBO J (1993) 4.32
Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med (1967) 4.09
DnaJ-like proteins: molecular chaperones and specific regulators of Hsp70. Trends Biochem Sci (1994) 3.65
The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J Clin Invest (1972) 3.43
The ATP hydrolysis-dependent reaction cycle of the Escherichia coli Hsp70 system DnaK, DnaJ, and GrpE. Proc Natl Acad Sci U S A (1994) 3.33
Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation (1974) 3.29
Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA (1994) 3.11
Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med (1967) 3.09
Studies of the proteins in human plasma very low density lipoproteins. J Biol Chem (1969) 2.98
Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med (1967) 2.86
The YTA10-12 complex, an AAA protease with chaperone-like activity in the inner membrane of mitochondria. Cell (1996) 2.80
A dual role for mitochondrial heat shock protein 70 in membrane translocation of preproteins. J Cell Biol (1993) 2.61
Molecular chaperones in protein folding: the art of avoiding sticky situations. Trends Biochem Sci (1994) 2.44
Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation (1984) 2.41
Prohibitins regulate membrane protein degradation by the m-AAA protease in mitochondria. Mol Cell Biol (1999) 2.34
Pathogenesis and management of lipoprotein disorders. N Engl J Med (1985) 2.31
The reaction cycle of GroEL and GroES in chaperonin-assisted protein folding. Nature (1993) 2.30
A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun (1970) 2.24
Lipoprotein metabolism. Adv Lipid Res (1975) 1.90
Molecular chaperones cooperate with PIM1 protease in the degradation of misfolded proteins in mitochondria. EMBO J (1994) 1.80
Total inhibition of hepatic beta-lipoprotein production in the rat by orotic acid. J Biol Chem (1967) 1.79
Membrane protein degradation by AAA proteases in mitochondria: extraction of substrates from either membrane surface. Mol Cell (2000) 1.73
Control of folding and membrane translocation by binding of the chaperone DnaJ to nascent polypeptides. Proc Natl Acad Sci U S A (1993) 1.72
Declining mortality in coronary heart disease. Arteriosclerosis (1982) 1.70
Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia. J Clin Invest (1974) 1.66
Chaperone-like activity of the AAA domain of the yeast Yme1 AAA protease. Nature (1999) 1.62
Limitations of the electrocardiographic response to exercise in predicting coronary-artery disease. N Engl J Med (1975) 1.61
On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein. Biochim Biophys Acta (1973) 1.59
The formation of respiratory chain complexes in mitochondria is under the proteolytic control of the m-AAA protease. EMBO J (1998) 1.56
Why drugs fail--a study on side effects in new chemical entities. Curr Pharm Des (2005) 1.54
A comparison of heritable abnormal lipoprotein patterns as defined by two different techniques. J Clin Invest (1969) 1.54
The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation (1984) 1.54
High density lipoprotein metabolism in man. J Clin Invest (1977) 1.53
Role of the ABC transporter Mdl1 in peptide export from mitochondria. Science (2001) 1.53
Progress in prevention of cardiovascular disease. Prev Med (1978) 1.53
Metabolsim of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteininemic subjects. J Lipid Res (1978) 1.53
Cardiovascular pathology in hyperlipoproteinemia. Anatomic observations in 42 necropsy patients with normal or abnormal serum lipoprotein patterns. Am J Cardiol (1973) 1.52
Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest (1974) 1.50
The nature of pre beta (very low density) lipoproteins. J Clin Invest (1966) 1.48
Lipoprotein apoprotein metabolism. J Lipid Res (1978) 1.48
Kidney instant monitoring (K.IN.G): a new analyzer to monitor kidney function. Minerva Anestesiol (2010) 1.47
Yta10p is required for the ATP-dependent degradation of polypeptides in the inner membrane of mitochondria. FEBS Lett (1994) 1.46
Lipid and carbohydrate abnormalities in patients with angiographically documented coronary artery disease. Am J Cardiol (1969) 1.45
Production of beta-lipoprotein by intestine in the rat. J Biol Chem (1968) 1.45
Comparison of the triglyceride lipase of liver, adipose tissue, and postheparin plasma. J Lipid Res (1972) 1.44
Thyroid function in paediatric and young adult patients after sarcoma therapy: a report from the Late Effects Surveillance System. Clin Endocrinol (Oxf) (2007) 1.42
Current therapy for hypercholesterolemia. JAMA (1989) 1.42
On the protein defect in abetalipoproteinemia. N Engl J Med (1971) 1.40
Adenine phosphoribosyltransferase deficiency: a previously undescribed genetic defect in man. J Clin Invest (1968) 1.38
Hsp78, a Clp homologue within mitochondria, can substitute for chaperone functions of mt-hsp70. EMBO J (1995) 1.36
Biosynthesis of lymph and plasma lipoprotein apoproteins by isolated perfused rat liver and intestine. J Lipid Res (1973) 1.35
Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ Res (1973) 1.33
Neonatal diagnosis of familial type-II hyperlipoproteinaemia. Lancet (1973) 1.32
Further separation of the apoproteins of the human plasma very low density lipoproteins. Biochim Biophys Acta (1970) 1.28
Afferents to the flocculus of the cerebellum in the rhesus macaque as revealed by retrograde transport of horseradish peroxidase. J Comp Neurol (1985) 1.26
Electron microscopic study on reassembly of plasma high density apoprotein with various lipids. Biochim Biophys Acta (1971) 1.24
The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med (1975) 1.24
Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N Engl J Med (1978) 1.23
Mitochondrial Hsp78, a member of the Clp/Hsp100 family in Saccharomyces cerevisiae, cooperates with Hsp70 in protein refolding. FEBS Lett (2001) 1.23
Diagnosis and management of hyperlipoproteinemia. Am J Cardiol (1968) 1.23
Immunoreactive insulin, glucose tolerance, and carbohydrate inducibility in types II, 3, IV, and V hyperlipoproteinemia. Diabetes (1969) 1.22
The decline in cardiovascular disease mortality. Annu Rev Public Health (1981) 1.22
The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab (1983) 1.22
Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA (2000) 1.21
Yta10p, a member of a novel ATPase family in yeast, is essential for mitochondrial function. FEBS Lett (1994) 1.20
Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet (1987) 1.20
Selective measurement of two different triglyceride lipase activities in rat postheparin plasma. J Lipid Res (1973) 1.15
Treatment of hyperlipidemia. N Engl J Med (1974) 1.15
The lipoproteins and lipid transport in abetalipoproteinemia. J Clin Invest (1966) 1.15
CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL--an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol (1997) 1.14
Identity of very low density lipoprotein apoproteins of plasma and liver Golgi apparatus. Science (1970) 1.14
Further characterization of apolipoproteins from the human plasma very low density lipoproteins. J Biol Chem (1970) 1.14
Characterization, subcellular localization, and partial purification of a heparin-released triglyceride lipase from rat liver. J Biol Chem (1973) 1.14
Plasma-triglycerides in regulation of H.D.L.-cholesterol levels. Lancet (1978) 1.13
Evidence for the identity of the major apoprotein in low density and very low density lipoproteins in normal subjects and patients with familial hyperlipoproteinemia. J Clin Invest (1972) 1.13
Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med (1967) 1.12
Further characterization of the apolipoproteins of rat plasma lipoproteins. Biochemistry (1970) 1.12
Studies on the protein defect in Tangier disease. Isolation and characterization of an abnormal high density lipoprotein. J Clin Invest (1972) 1.12
A new mechanism of exogenous hyperglyceridemia. Ann Intern Med (1969) 1.11
Metabolic fate of rat and human lipoprotein apoproteins in the rat. J Lipid Res (1973) 1.10
Acute tendinitis and arthritis. A presenting symptom of familial type II hyperlipoproteinemia. JAMA (1968) 1.09
Neuropathy in Tangier disease. Alpha-Lipoprotein deficiency manifesting as familial recurrent neuropathy and intestinal lipid storage. Arch Neurol (1967) 1.09
Effects of hyperlipoproteinemias and their treatment on the peripheral circulation. J Clin Invest (1970) 1.09
Stroke decline: implications and prospects. N Engl J Med (1979) 1.09
Decision-making in planning large-scale comparative studies. Ann N Y Acad Sci (1978) 1.07
Afferents to the abducens nucleus in the monkey and cat. J Comp Neurol (1986) 1.07
Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens. Mutat Res (1998) 1.06
Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain. Biochem J (2000) 1.06
The metabolism of very low density lipoprotein proteins. II. Studies on the transfer of apoproteins between plasma lipoproteins. Biochim Biophys Acta (1972) 1.06
ATP-dependent proteolysis in mitochondria. m-AAA protease and PIM1 protease exert overlapping substrate specificities and cooperate with the mtHsp70 system. J Biol Chem (1998) 1.05
Observations on the conformation of human beta lipoprotein: evidence for the occurrence of beta structure. Proc Natl Acad Sci U S A (1968) 1.05
Fractionation of the C-apoproteins from human plasma very low density lipoproteins. J Biol Chem (1973) 1.05
Amelioration of hypertriglyceridaemia by progestational drugs in familial type-V hyperlipoproteinaemia. Lancet (1969) 1.05
Strategies for efficient lead structure discovery from natural products. Curr Med Chem (2006) 1.04